CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that data from the physician-initiated compassionat
VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) today announced it has launched the second phase of its global headquarters expansion by breaking ground on its new facility in Vancouver, Canada. The 380,000-square-foot tech c
New board members bring significant leadership experience in the biotech sector VANCOUVER, British Columbia--(BUSINESS WIRE)--#Biomanufacturing--Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to tr
-- Completion of Adelia milestones marks promising path toward clinical drug development -- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psy
VANCOUVER, British Columbia--(BUSINESS WIRE)--Today, ABOzymes has unveiled a new identity, including a new name - “Avivo”. The update reflects the evolution of the Company since its founding in 2020 while maintaining the Company’s founding vision
OTTAWA, Ontario--(BUSINESS WIRE)--#HR--Today, BioTalent Canada launched the Building Workplace Resiliency resources for their new I.D.E.A.L. Biosciences Employer recognition program. In addition to providing guidance to employers looking to submit applica
Company continues to build out plans for International Expansion of Patented Upcycling Technology SUMMERLAND, British Columbia--(BUSINESS WIRE)--Crush Dynamics Inc. (CrushDynamics) was privileged to host the Honorable Mary Ng, Minister of International T
Five abstracts underscore the long-term safety and efficacy of voclosporin, including in Latino patients and patients with Class V lupus nephritis Data presentation on pre-clinical asset AUR200 reinforces Aurinia’s commitment to autoimmune disease VIC
DUBLIN--(BUSINESS WIRE)--The "Rare Disease Genetic Testing Market Size, Share & Trends Analysis Report by Disease Type (Neurological, CVDs), by Specialty (Molecular, Biochemical), by Technology (NGS, PCR-based), by End Use, and Segment Forecasts, 2022
Approval follows the positive opinion granted by European Committee for Medicinal Products for Human Use (CHMP) in July 2022 LUPKYNIS is the first oral medicine approved in both the U.S. and Europe for the treatment of adults living with active lupus ne
Our partner BioTalent Canada has launched the Building Workplace Resiliency resources for its I.D.E.A.L. Biosciences Employer Recognition Program. This program served as a guide for employers seeking to submit fall program applications.
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.